

Applicants: Ron S. Israeli et al.  
U.S. Serial No.: 10/012,169  
Filed: October 24, 2001

Pending Claims 24-29

24. A method of killing cancerous cells comprising: providing a monoclonal antibody which, when contacted with an extracellular domain of prostate specific membrane antigen, binds to the extracellular domain of prostate specific membrane antigen; and contacting vascular endothelial cells proximate to the cancerous cells with the monoclonal antibody under conditions effective to permit both binding of the monoclonal antibody to the vascular endothelial cells proximate to the cancerous cells and killing the cancerous cells; said monoclonal antibody being bound to a drug effective to kill the cancerous cells upon binding of the monoclonal antibody to said vascular endothelial cells proximate to the cancerous cells.
25. The method of claim 24, wherein the cancerous cells are prostate cancerous cells.
26. The method of claim 24, wherein the cancerous cells are kidney cells or colon cells.
27. The method of claim 24, wherein said contacting is carried out in a subject and comprises administering the monoclonal antibody to the subject under conditions effective to permit both binding of the monoclonal antibody to vascular endothelial cells proximate to the cancerous cells and killing the cancerous cells.

Applicants: Ron S. Israeli et al.  
U.S. Serial No.: 10/012,169  
Filed: October 24, 2001

28. The method of claim 27, wherein the subject is a human.

29. The method of claim 27, wherein said administering is carried out orally, parenterally, subcutaneously, intravenously or intramuscularly.